PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

No benefit found from BP drug in treatment of recently hospitalized heart failure patients

Equal rates of death, cardiac events found in recently hospitalized heart failure patients on renin inhibitor or placebo in ASTRONAUT trial

2013-03-12
(Press-News.org) SAN FRANCISCO (March 11, 2013) —Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

Heart failure is the leading cause of hospitalization for people over age 65, costing Medicare billions of dollars annually, and researchers are always on the lookout for more effective treatments.

The Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) is an international, double-blind study that enrolled stable patients hospitalized for heart failure and followed them after discharge. Patients were randomized to receive either aliskiren, starting at 150 mg and increasing to 300 mg, or placebo, in addition to other standard heart failure therapies. After six months, patients in both groups had a similar likelihood of cardiovascular death or re-hospitalization for heart failure.

However, patients in the aliskiren group did show a statistically significant and sustained drop in one of the study's secondary endpoints, blood levels of N-terminal proB-type natriuretic peptide (NT-proBNP)—a hormone that increases as heart failure progresses.

"In the majority of cases, patients' natriuretic peptide levels correlate with their stage of heart failure and can help physicians plan treatment," said Mihai Gheorghiade, MD, professor at Northwestern University's Feinberg School of Medicine and lead author of the ASTRONAUT study. "It was surprising to see that our study drug did positively affect patients' levels of this peptide, but this positive effect did not translate into reduced mortality or hospitalizations as we would have expected."

While patients taking aliskiren in addition to evidence-based heart failure therapy showed improvements in natriuretic peptide levels over time, they also had significantly higher rates of hyperkalemia (overly high potassium levels), worsening renal function and hypotension (abnormally low blood pressure). According to Dr. Gheorghiade, it may be that the side effects of the treatment regimen "blunted" its beneficial effects.

"Just like if you give a patient with a blood clot that is causing a heart attack a medication that is effective in dissolving the clot but then that medicine causes bleeding—you may have stopped the heart attack, but this prevents the drug from being highly beneficial," he said.

ASTRONAUT enrolled 1,615 patients at 316 centers who were hospitalized for heart failure and were stable enough at discharge to safely receive high doses of aliskiren. Both groups were similar at baseline with stable kidney function, a low ejection fraction (reduced blood pumped by the heart) and high NTproBNP. Both groups also had similar rates of high blood pressure, coronary artery disease, diabetes and atrial fibrillation. Standard heart failure therapy was comparable between groups. Patients were initially followed every two weeks, and then every three months, for one year.

"Despite all the evidence-based therapies available for heart failure patients today, their chances of dying or returning to hospital are still unacceptably high," said Dr. Gheorghiade. "There is a huge unmet need to improve patient outcomes after discharge, which is what we were hoping our study would do."

Dr. Gheorghiade said that this particular patient population has a much higher mortality rate than outpatients with chronic heart failure, even though the problems that cause them to be hospitalized generally respond well to standard in-hospital therapies. Previous studies have shown that 30 percent of patients hospitalized for heart failure are readmitted within one to two months. This is significant because hospitalization is one of the strongest predictors of death among outpatient heart failure patients.

Among patients receiving aliskiren, the likelihood of death was reduced in patients without diabetes but not in those with diabetes. This may be due to the fact that people with diabetes are already at risk for conditions such as hyperkalemia, kidney impairment and hypotension that may be observed with aliskiren, particularly when used on top of other standard therapies. However, the exact mechanisms that cause opposite effects in patients with or without diabetes are not clearly understood and deserve further analysis, Dr. Gheorghiade said. He added that although these subgroup findings are intriguing, they must be interpreted with caution because of the statistical limitations of this type of analysis.

Similar adverse effects among patients with diabetes and renal impairment, along with an increased incidence of non-fatal stroke, led to the termination of another trial with aliskiren called ALTITUDE in 2011. The patients in the ASTRONAUT study were a completely different population, explained Dr. Gheorghiade. He further noted that the ASTRONAUT study did not reproduce the pattern of clinical outcomes observed in ALTITUDE, and in particular, aliskiren-treated patients in ASTRONAUT had a lower risk of stroke than the placebo group.

Dr. Gheorghiade recommended that additional studies be done among non-diabetic patients with heart failure to see whether renin inhibition can still deliver positive results.

### The ASTRONAUT study was sponsored by Swiss pharmaceutical company Novartis. Dr. Gheorghiade serves as a consultant for Novartis.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.

This study will be simultaneously published in the Journal of the American Medical Association, and will appear in the March 20 print edition with online release at the time of presentation.

Dr. Gheorghiade will be available to the media on Monday, March 11 at 12:15 p.m., in Moscone Center, South, Room 300.

Dr. Gheorghiade will present the study "The ASTRONAUT Study: Aliskiren Trial on Acute Heart Failure Outcomes" on Monday, March 11 at 11:15 a.m., in Moscone Center, South, Esplanade Ballroom.


ELSE PRESS RELEASES FROM THIS DATE:

Erectile dysfunction drug fails for diastolic heart failure patients

2013-03-12
SAN FRANCISCO (March 11, 2013) — Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session. The RELAX Study is the first multicenter trial to look at the effect of chronic therapy with sildenafil in diastolic heart failure. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor, a class of drugs used to treat erectile dysfunction and certain types of pulmonary arterial hypertension. ...

Low T3 syndrome predicts unfavorable outcomes in surgical patients with brain tumor

2013-03-12
Charlottesville, VA (March 12, 2013). In a study of 90 patients undergoing surgery for brain tumor, researchers in Lithuania (Lithuanian University of Health Sciences) and the United States (University of North Carolina at Chapel Hill and Brigham & Women's Hospital, Harvard University) have discovered that the finding of low T3 (triiodothyronine) syndrome is predictive of unfavorable clinical outcomes and depressive symptoms. Details of this study are furnished in the article "Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor ...

What impact does a day of roller derby have on our skin microbiome?

2013-03-12
The human skin is home to countless microorganisms that we can't see, but these microbes help define who we are. Our invisible passengers – known as the skin microbiome - contribute to our health in numerous ways including educating our immune system, protecting us from pathogens, and mediating skin disorders. In a new study, researchers investigated how the skin microbiome is transmitted between players in a contact sport, using roller derby as their model system. The skin is the largest organ and an important barrier that regulates microbial entry into the human body. ...

Hereditary neurodegeneration linked to ADP-ribose modification

2013-03-12
HEIDELBERG, 12 March 2013 – Attaching chains of the small molecule ADP-ribose to proteins is important for a cell's survival and the repair of DNA damage, making this process a promising target for the development of new cancer drugs. Researchers have now identified a much sought after enzyme that removes such ADP-ribose modifications from proteins by studying a genetic mutation that causes neurodegenerative disease in humans. These findings, published today in The EMBO Journal, suggest that not only addition but also removal of ADP-ribose from proteins is essential for ...

Extremely rare triple quasar found

2013-03-12
Pasadena, CA—For only the second time in history, a team of scientists--including Carnegie's Michele Fumagalli--have discovered an extremely rare triple quasar system. Their work is published by Monthly Notices of the Royal Astronomical Society. It is available online. Quasars are extremely bright and powerful sources of energy that sit in the center of a galaxy, surrounding a black hole. In systems with multiple quasars, the bodies are held together by gravity and are believed to be the product of galaxies colliding. It is very difficult to observe triplet quasar ...

Stanford researchers map out an alternative energy future for New York

2013-03-12
New York Gov. Andrew Cuomo will soon decide whether to approve hydraulic fracturing for natural gas in the state. To date, no alternative to expanded gas drilling has been proposed. But a new study finds that it is technically and economically feasible to convert New York's all-purpose energy infrastructure to one powered by wind, water and sunlight (WWS). The plan, scheduled for publication in the journal Energy Policy, shows the way to a sustainable, inexpensive and reliable energy supply that creates local jobs and saves the state billions of dollars in pollution-related ...

Fluorescent light revealed as gauge of coral health

2013-03-12
Coral reefs not only provide the world with rich, productive ecosystems and photogenic undersea settings, they also contribute an economic boost valued at hundreds of billions of dollars. But their decline in recent years due to a variety of threats—from pollution to climate warming—has lent urgency to the search for new ways to evaluate their health. A new study by Scripps Institution of Oceanography at UC San Diego scientists has revealed that fluorescence, the dazzling but poorly understood light produced by corals, can be an effective tool for gauging their health. As ...

Pesticide application as potential source of noroviruses in fresh food supply chains

2013-03-12
Human norovirus (hNoV), also known as the winter vomiting bug, is one of the most common stomach bugs in the world. The virus is highly contagious, causing vomiting and diarrhea, and the number of affected cases is growing. Currently there is no cure; sufferers have to let the virus run its course for a few days. The consumption of fresh produce is frequently associated with outbreaks of hNoV but it remains difficult to identify where in the supply chain the virus first enters production. A new study, published in the International Journal of Food Microbiology investigated ...

Fertilizers could help tackle nutritional deficiency in African country, researchers say

2013-03-12
Enriching crops by adding a naturally-occurring soil mineral to fertilisers could potentially help to reduce disease and premature death in the African country of Malawi, researchers have said. An international study led by academics at The University of Nottingham has shown that dietary deficiency of the mineral selenium — which plays a vital role in keeping the immune system healthy and fighting illness — is likely to be endemic among the Malawi population. They found that most Malawi soils cannot supply enough selenium for adequate human nutrition and, in a paper ...

Friend or foe: Babies choose sides early

2013-03-12
Babies have a dark side under their cute exteriors, according to University of British Columbia-led study that finds infants as young as nine months embrace those who pick on individuals who are different from them. While previous research has shown that babies generally prefer kind actors, the new study – published by the Association for Psychological Science – is the first to suggest that infants condone antisocial behavior when it is directed at individuals who are dissimilar. "Our research shows that by nine months, babies are busy assessing their surroundings, ...

LAST 30 PRESS RELEASES:

Are lifetimes of big appliances really shrinking?

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

[Press-News.org] No benefit found from BP drug in treatment of recently hospitalized heart failure patients
Equal rates of death, cardiac events found in recently hospitalized heart failure patients on renin inhibitor or placebo in ASTRONAUT trial